Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2016 by AstraZeneca
Information provided by (Responsible Party):
AstraZeneca Identifier:
First received: October 21, 2010
Last updated: September 16, 2016
Last verified: September 2016
No Study Results Posted on for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: April 2018
  Estimated Primary Completion Date: September 2017 (Final data collection date for primary outcome measure)